Amgen Inc. DEF 14A: Executive Compensation Details
Ticker: AMGN · Form: DEF 14A · Filed: 2025-04-09T00:00:00.000Z
Sentiment: neutral
Topics: executive-compensation, sec-filing, equity-awards
Related Tickers: AMGN
TL;DR
Amgen's 2024 exec comp details are out - stock options & equity awards in focus.
AI Summary
Amgen Inc. filed its DEF 14A on April 9, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock options, equity awards, and changes in the fair value of outstanding awards for both principal executive officers (PEO) and non-PEO/non-executive officers.
Why It Matters
This filing provides transparency into how Amgen Inc. compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present immediate financial risks.
Key Numbers
- 2024 — Fiscal Year (Executive compensation data pertains to this year.)
- 2023 — Prior Fiscal Year (Comparative data for executive compensation.)
Key Players & Entities
- AMGEN INC (company) — Filer
- 0000318154 (company) — Central Index Key
- 20250409 (date) — Filing Date
- 20250523 (date) — Conformed Period of Report
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the total compensation for Amgen's Principal Executive Officer (PEO) for the fiscal year 2024?
The filing indicates data related to PEO members for the fiscal year 2024, but specific total compensation figures are not provided in this excerpt.
What types of equity awards are detailed in the filing?
The filing details changes in the fair value of outstanding and unvested equity awards granted in prior years, as well as year-end fair values of equity awards granted in covered years.
When was this DEF 14A filing submitted to the SEC?
The filing was submitted on April 9, 2025.
What is the fiscal year end for Amgen Inc.?
Amgen Inc.'s fiscal year ends on December 31.
Does the filing include compensation details for non-executive officers?
Yes, the filing includes data for non-PEO non-executive members regarding changes in the fair value of outstanding and unvested equity awards.
From the Filing
0000950170-25-052315.txt : 20250409 0000950170-25-052315.hdr.sgml : 20250409 20250409083050 ACCESSION NUMBER: 0000950170-25-052315 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 107 CONFORMED PERIOD OF REPORT: 20250523 FILED AS OF DATE: 20250409 DATE AS OF CHANGE: 20250409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 25823902 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 DEF 14A 1 amgn-20250408.htm DEF 14A DEF 14A 0000318154 false DEF 14A do not grant 0000318154 2024-01-01 2024-12-31 0000318154 6 2024-01-01 2024-12-31 0000318154 4 2024-01-01 2024-12-31 0000318154 7 2024-01-01 2024-12-31 0000318154 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0000318154 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2024-01-01 2024-12-31 0000318154 2023-01-01 2023-12-31 0000318154 ecd:NonPeoNeoMember amgn:SummaryCompensationTableValueOfStockAwardsMember 2024-01-01 2024-12-31 0000318154 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0000318154 amgn:StockOptionFairValuesMember 2024-12-31 0000318154 amgn:StockOptionFairValuesMember 2024-01-01 2024-12-31 0000318154 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2024-01-01 2024-12-31 0000318154 amgn:SummaryCompensationTableValueOfOptionAwardsMember ecd:PeoMember 2024-01-01 2024-12-31 0000318154 2 2024-01-01 2024-12-31 0000318154 amgn:SummaryCompensationTableValueOfStockAwardsMember ecd:PeoMember 2024-01-01 2024-12-31 0000318154 2022-01-01 2022-12-31 0000318154 ecd:NonPeoNeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2024-01-01 2024-12-31 0000318154 ecd:NonPeoNeoMember amgn:SummaryCompensationTableValueOfOptionAwardsMember 2024-01-01 2024-12-31 0000318154 2020-01-01 2020-12-31 0000318154 2021-01-01 2021-12-31 0000318154 1 2024-01-01 2024-12-31 0000318154 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0000318154 5 2024-01-01 2024-12-31 0000318154 amgn:PerformanceUnitFairValuesMember 2024-12-31 0000318154 amgn:PerformanceUnitFairValuesMember 2024-01-01 2024-12-31 0000318154 3 2024-01-01 2024-12-31 iso4217:USD xbrli:shares xbrli:pure iso4217:USD     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑   Filed by the registrant       ☐  Filed by a party other than the registrant   Check the appropriate box:       ☐ Preliminary Proxy Statement       ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2))       ☑ Definitive Proxy Statement       ☐ Definitive Additional Materials       ☐ Soliciting Material Pursuant to Section 240.14a-12     AMGEN INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant)   Payment of filing fee (check the appropriate box):       ☑ No fee required.       ☐ Fee paid previously with preliminary materials.       ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.